Mostrando 3 resultados de: 3
1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients
ArticleAbstract: Conventional treatment of non-small cell lung cancer (NSCLC) has apparently reached a plateau of effPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Aguirre F., Alfonso S., Alonso D.F., Barroso M.C., Carmen Elena Viada, De La Torre A.V., Díaz R.M., Gabri M.R., Gómez R., Hernández A.M., Macías A.E., Pérez K., Pérez R., Rodríguez J., Santiesteban E.R., Suárez E., Toledo D., Vázquez A.M.Fuentes:scopusEvaluation of racotumomab for the treatment of lung cancer: Meta-analysis of controlled trials of the CIM
ArticleAbstract: Racotumomab is a therapeutic cancer vaccine entirely developed in Cuba and licensed in the country fPalabras claves:immunotherapy, Non-small cell lung cancer, Oncological vaccines, Racotumomab, Vaccinal treatmentAutores:Alfonso S., Aliuska Frías, Ballesteros J., Carmen Elena Viada, Hernández M., Mabel Álvarez, Macías A.E., Martha M. Fors-López, Quintero J., Robaina M.Fuentes:scopusImmunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients
ArticleAbstract: Increased levels of NeuGc-containing gangliosides have been described in human breast cancer. A contPalabras claves:Breast Cancer, cancer vaccine, Clinical trial, Ganglioside, immunotherapy, NeuGcGM3, patientsAutores:Cardoso J., Carmen Elena Viada, Carr A., De La Torre A.V., Díaz R., Fernandez L.E., Macías A.E., Marinello P., Mazorra Z., Mulens V., O'Farrill M., Pérez R., Rodríguez R., Saurez G., Tania CrombetFuentes:scopus